MetaCap

Evotec (EVO) vs Gyre Therapeutics (GYRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Gyre Therapeutics (GYRE) has outperformed Evotec (EVO) over the past year, losing 44.2% versus a loss of 55.6%. Over five years, GYRE leads with a -77.5% price change compared with -94.4% for EVO. Evotec is the larger company by market cap ($469.1 million vs $460.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVO-55.56%GYRE-44.24%
+35%-13%-60%
Nov 21, 20251 yearNov 20, 2026
EVO-94.42%GYRE-78.58%
+59%-21%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVO versus GYRE key metrics
MetricEVOGYRE
Share price$1.32$4.21
Market cap$469.11M$460.79M
1-day change-8.97%-6.86%
YTD return-57.14%-40.37%
1-year return-55.56%-44.24%
5-year return-94.44%-77.55%
Forward P/E—70.17
EPS (TTM)$-0.59$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$116.59M
Revenue growth (YoY)—+10.24%
Net income (latest FY)—$9.88M
Gross margin—95.35%
Operating margin—9.85%
Net margin—8.47%
52-week high$3.87$9.14
52-week low$1.32$3.97
Distance from 52-week high-65.89%-53.94%
Analyst consensusbuystrong_buy
Avg. price target upside+237.12%+343.47%
Average volume109.16K181.04K
Shares outstanding355.39M109.45M
Employees4,379625
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GYRE has outperformed EVO by 11.3 percentage points over the past year.

About Evotec

EVO stock →

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics.

Health Care · Biotechnology: Pharmaceutical Preparations · 4,379 employees

About Gyre Therapeutics

GYRE stock →

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees

EVO vs GYRE FAQ

Which is bigger, Evotec or Gyre Therapeutics?

Evotec (EVO) is larger, with a market capitalization of $469.11M compared with $460.79M for Gyre Therapeutics (GYRE).

Which stock has performed better over the past year, EVO or GYRE?

GYRE returned -44.24% over the past 12 months, compared with -55.56% for EVO (price return, excluding dividends). Past performance does not predict future results.

Are Evotec and Gyre Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons